MedTrace Logo

Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells

NCT03628612 · Status: ENROLLING_BY_INVITATION · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 500

Last updated 2025-08-07

No results posted yet for this study

Summary

Long-term follow-up of patients exposed to an AUTO CAR T cell therapy for up to 15 years following their first AUTO CAR T cell therapy infusion.

Conditions

  • Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy
  • Multiple Myeloma
  • DLBCL
  • ALL, Adult and Pediatric
  • T Cell Lymphoma

Interventions

BIOLOGICAL

AUTO CAR T cell therapy

No study drug is administered in this study. Patients previously treated with AUTO CAR T cell therapy will be monitored for safety following the first infusion.

Sponsors & Collaborators

  • Autolus Limited

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
1 Year
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-02
Primary Completion
2043-07-31
Completion
2043-12-31

Countries

  • United States
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03628612 on ClinicalTrials.gov